First human trial of senolytics: promising, and very early

This month, researchers published the first-in-human pilot study of senolytic drugs, dasatinib combined with quercetin, in patients with idiopathic pulmonary fibrosis, a progressive age-related lung disease.

Some context helps. Senescent cells are cells that have permanently stopped dividing, usually in response to damage or stress, but have not died. They accumulate with age, and they release a mix of inflammatory signals that can affect the tissue around them. In animal studies, removing these cells has improved several age-related problems. Senolytics are drugs designed to kill senescent cells selectively while sparing normal ones.

Dasatinib is an existing cancer drug, and quercetin is a compound found in many plants. Used together, they were among the first combinations shown to clear senescent cells in mice.

Idiopathic pulmonary fibrosis is a serious disease in which lung tissue becomes progressively scarred, making it harder to breathe. Senescent cells have been linked to the disease, which made it a logical place to test the idea in people.

What they found

In a small, open-label study, patients showed improvements in physical function measures such as walking distance, and the treatment was generally tolerated.

Those are meaningful outcomes for patients, because physical function is closely tied to quality of life. But they are also outcomes that can be influenced by expectations, especially when everyone knows they are receiving the treatment.

Exciting, and it should be read carefully.

My perspective

This is exciting, and it should be read carefully. The study was small, had no placebo group, and was designed to test feasibility, not efficacy. Feasibility means asking whether the treatment can be given safely and whether it is worth testing properly. It does not tell us whether the drugs work.

Open-label studies have a known weakness. When patients and researchers know who is being treated, improvements can reflect motivation, attention and hope as much as biology. Only a randomized, placebo-controlled trial can separate those effects from a real drug effect.

Senescent cells are also not purely harmful: they help suppress cancer and heal wounds. Senescence is one of the ways the body stops damaged cells from becoming tumours, and senescent cells play a role in tissue repair. Clearing them is not automatically good. Timing, dose and which tissues are affected will matter, and long-term effects are unknown.

My background is in aging biology, and I have seen many results that looked strong in model organisms and weaker in people. That is not a reason for pessimism. It is a reason to keep the standard of evidence high and to resist turning a pilot study into a headline about reversing aging.

Still, moving the idea of clearing “zombie cells” from mice into people is a real milestone for aging research. For years, the field has been criticized for producing results in yeast, worms and mice that never reach patients. This is a concrete step across that gap, and it targets aging biology to treat a specific disease, which is the most realistic path forward.

The next trials will tell us whether it holds. I will be watching for larger, controlled studies with clear endpoints. If the effect survives that test, it will be one of the most important developments in the field.